Melbourne, May 12, 2026, 05:10 AEST
CSL Limited shares tumbled 16% on Monday, closing at A$100.75—after dipping under A$100 intraday, a level not seen in nearly ten years. The Australian blood-products and vaccine manufacturer slashed its forecast for fiscal 2026 and warned of around US$5 billion in fresh non-cash, pre-tax impairments. These writedowns hit asset values but don’t drain cash right away.
This wasn’t just a regular earnings update. Interim Chief Executive Gordon Naylor delivered his 90-day review since stepping in back in February, spotlighting Vifor—the business CSL acquired for US$11.7 billion in 2022—right back in the thick of the company’s issues.
ASX trading doesn’t resume until Tuesday, so Monday’s closing figures are still the latest available. Regular ASX cash-market hours pick up just before 10 a.m. and go through to 4 p.m. in Sydney. CSL has now dropped roughly 41% year to date, and the 12-month slide extends past 57%, according to ABC.
Selling pressure spilled across the broader market. According to Reuters, the S&P/ASX 200 closed down 0.5% at 8,701.8. CSL’s slump dragged the healthcare index down 6.5%, taking it to its lowest point in more than eight years.
CSL is now guiding for FY26 revenue to land around US$15.2 billion, with NPATA pegged at roughly US$3.1 billion, both figures stripped of currency swings. The company’s favored profit metric, NPATA, excludes amortisation tied to acquired intellectual property and factors out big-ticket one-offs like restructuring or impairment costs.
The company pointed to three big revenue drags: roughly US$300 million tied to U.S. immunoglobulin inventories returning to typical levels, another US$200 million hit from lower albumin prices in China, and close to US$150 million due to fallout from the Middle East conflict, HEMGENIX’s slower growth pace, plus rising competition in iron. Immunoglobulin covers antibody-rich drugs made from plasma, while albumin is also plasma-derived.
CSL’s “growth initiatives are working,” Naylor said, though the “financial benefits will take longer” to materialize than the company had originally thought. CSL Behring, the plasma business, is still on track for second-half revenue growth. CSL Seqirus, which makes flu vaccines, is now expected to do a bit better than previously forecast.
During the investor call, Naylor insisted there’s “no fundamental shift” in the company’s strategy, chalking up the problem to execution issues, Fierce Pharma reported. CFO Ken Lim flagged “excess Ig inventory” in the channel, and Naylor admitted CSL had been “slow to respond” as rivals ramped up competition in the immunoglobulin market. Fierce Pharma
This is where competition bites harder. Takeda Pharmaceutical, Grifols, and Octapharma all show up with CSL on the roster of top immunoglobulin and plasma-derived drug makers, according to industry trackers. So, even with rising demand, CSL isn’t insulated if competitors speed up on pricing, supply, or tweak their product mix.
Tim Waterer, chief market analyst at KCM Trade, noted CSL’s slide might start attracting long-term investors—provided management can stabilize things. He cautioned, though, that the healthcare sector shouldn’t assume every company is shielded from higher costs or changing demand.
Leadership moves at CSL are far from settled. The company said its hunt for a permanent CEO continues. Naylor, after handing over, plans to stay on as a non-executive director. Chief Commercial Officer Andy Schmeltz is heading for retirement. On July 1, Diego Sacristan steps in to lead commercial operations at both CSL Behring and CSL Vifor.
Still, the reset carries its share of risk. CSL could run into more trouble if the U.S. immunoglobulin destocking drags on, China albumin pricing slips again, or rivals in iron and gene therapy ramp up the pressure. The company flagged that impairments may shift as they continue their review, and changes could depend on business moves, audit findings, or what the board decides. A clearer picture is promised with the full-year results on Aug. 18.
